A. Palumbo emphasizes that novel monoclonal antibodies will transform care in patients with multiple myeloma in the way that R-CHOP regimen did in the field of lymphoma. The current regimens have already doubled the survival in multiple myeloma and there is a lot of expectations for further improvement with new agents. He elaborates the results from the ELOQUENT-2 study of lenalidomide/ dexamethasone with or without elotuzumab, ENDEAVOR study of carfilzomib/ dexamethasone vs bortezomib/ dexamethasone, and daratumumab monotherapy.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen Lilly Oncology

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Roche